Core Viewpoint - The article discusses the strategic acquisition of Huayang Technology by Pengding Holdings, facilitated by Jinding Capital, highlighting the unique role of Jinding as a deep service provider in the M&A process [2][3][11]. Group 1: Acquisition Overview - The acquisition involves Pengding Holdings, a leading global PCB company, acquiring a controlling stake in automotive sensor company Huayang Technology for 357 million yuan [2]. - This transaction is seen as a significant step for Pengding to deepen its presence in the automotive electronics sector while providing Huayang with a pathway for accelerated growth through industrial capital [3][5]. Group 2: Role of Jinding Capital - Jinding Capital played a crucial role in the acquisition, acting not just as a financial advisor but as a deep participant throughout the entire process, from identifying the target to finalizing the deal [3][11]. - The firm has a long-standing focus on the technology sector, particularly in semiconductors, and has built a robust ecosystem through partnerships with various companies [5][11]. Group 3: Strategic Matching - The transaction was initiated by Jinding Capital's proactive identification of Huayang Technology as a strategic opportunity, rather than a direct request from either party [5][6]. - Jinding recognized the complementary strengths of Huayang's technology and Pengding's manufacturing capabilities, leading to a strategic match that benefits both parties [6][7]. Group 4: Trust Building and Long-term Vision - Jinding Capital emphasized a philosophy of "long-termism" and "win-win" thinking to bridge the trust gap between the two companies, countering common concerns in M&A about control and valuation [7][8]. - The firm focused on future value creation rather than current asset disputes, which was reflected in the mixed financing structure of the deal [8][9]. Group 5: Comprehensive Service Model - Jinding Capital has developed a standardized, full-process service model for M&A, which includes strategic alignment, due diligence coordination, and negotiation facilitation [9][10]. - This model allows for a more efficient and effective transaction process, reducing misunderstandings and enhancing communication between parties [10][12]. Group 6: Industry Impact and Future Outlook - Jinding Capital's approach is reshaping the role of financial advisors in the context of strategic M&A, moving beyond traditional arbitrage to a focus on industry logic [11][12]. - The firm has successfully executed over 20 M&A transactions with a total valuation exceeding 10 billion yuan, establishing itself as a benchmark in the industry [13].

环球时报研究院12月29日发布的"2025年中国国际形象全球调查报告"显示，在46个国家、约5.17万份有 效样本的广泛覆盖中，习近平新时代中国特色社会主义思想获国际社会高度认同。"构建人类命运共同 体""绿水青山就是金山银山"获近八成国际民意认同，"全面从严治党""全面深化改革""以人民为中心"获 超过七成认同。发展中国家在上述五个方面的民意认同比例均超过八成，发达国家均超过六成。这份跨 越不同制度、文化与发展阶段的民意样本，为我们观察"世界如何看中国"提供了一面更真实直接的镜 子。 对中国理念的认同度，反映出的是国际社会在动荡世界中对确定性、可持续性的普遍追求。而国外民众 对中国的认知，正在形成更清晰的结构图景——既看重中国发展的现实成就，更期待理解中国提出的理 念与倡议。在保护主义抬头、冲突风险外溢、发展鸿沟扩大的背景下，越来越多国家热切期待着把安全 与发展统筹起来，把增长与公平贯通起来，处理好人与自然的关系。中国理念之所以能够获得更广泛共 鸣，关键在于立足和平、安全、发展、治理等时代性课题，以问题为牵引、以实践为支撑，形成了可复 制可推广的行动路径。 中国理念、中国方案之所以有如此深刻广泛的国际传播度 ...

Core Insights - The article highlights the transformative leadership of Shirley Zhao, the first local female president of Astellas in China, emphasizing her philosophy of "win-win" and her significant contributions to the company's growth and cultural transformation in the Chinese market [1][4][5]. Group 1: Company Growth and Performance - Under Zhao's leadership, Astellas China has achieved continuous growth, with a double-digit increase in fiscal year 2024 and a remarkable 32% growth in the first half of fiscal year 2025, making China a new growth engine for Astellas globally [4][5]. - The employee count increased by 50% from under 800 to 1,200 within a year, and the company was recognized as a "Great Employer in China" in early 2025 [5]. Group 2: Cultural and Strategic Transformation - Zhao faced challenges in cultural transformation, including employee acceptance, inter-departmental collaboration, and the need for speed and agility in a competitive market [7][8]. - She emphasized the importance of a unified vision among the management team and introduced a new cultural philosophy called "winning culture," focusing on patient value [9][11]. Group 3: Innovation and Product Development - Astellas China experienced a surge in its innovative product pipeline, particularly in oncology, with the introduction of groundbreaking therapies such as the first antibody-drug conjugate targeting Nectin-4 and the first monoclonal antibody targeting CLDN18.2 [13][14][15]. - The company achieved a record of seven product approvals in the previous year, showcasing its accelerated innovation [15]. Group 4: Market Access and Patient Accessibility - Zhao highlighted the importance of market access for ensuring that innovative therapies reach patients, sharing successful cases of therapies being included in national insurance programs [17][18]. - Astellas is also exploring innovative payment models to reduce patient financial burdens [18]. Group 5: Focus on Women's Health - Astellas is venturing into women's health, particularly focusing on managing menopause symptoms, addressing a significant unmet medical need in China [19][21]. - Zhao advocates for a societal shift in the perception of menopause, emphasizing the need for understanding and support for women during this transition [21]. Group 6: Strategic Localization - Astellas announced the establishment of its first contract manufacturing project and innovation research center in China, marking a significant step towards a complete localized supply chain [23][24]. - This localization strategy aims to enhance efficiency and ensure a stable supply chain while aligning with global headquarters [24][25]. Group 7: Future Outlook - Zhao stresses the importance of patent and data protection for fostering innovation in the pharmaceutical industry, welcoming recent government initiatives to enhance these protections [29]. - The vision for Astellas China includes increasing its global business share and securing more resources for Chinese patients [29][30].